Prochlorperazine transmucosal - Reckitt Benckiser

Drug Profile

Prochlorperazine transmucosal - Reckitt Benckiser

Alternative Names: Emezine

Latest Information Update: 08 Sep 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Reckitt Benckiser
  • Class Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 31 Dec 2008 Discontinued - Preregistration for Nausea and vomiting in USA (Transmucosal)
  • 28 Feb 2006 BioDelivery Sciences International has received a non-approvable letter from the FDA for Emezine in Nause and vomiting
  • 02 May 2005 Preregistration for Nausea and vomiting in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top